Researchers at the University of Alberta have recently reported that the drug DCA to tumor regression in a number of human cancer causing in animals grow.
The drug, dichloroacetate (DCA), used for years to treat rare metabolic disorder and is known to be quite safe. It is also not protected by patents and hence could be very cheap, much cheaper than standard drugs against cancer.
The best part is that DCA (dichloroacetate) is actually the cancer cells by their mitochondria, their main power generator to reactivate sound makes that turn cells cancerous and the other is fatal. The drug benvloedt not the normal cells of the body.
Evangelos Michelakis of the University of Alberta in Edmonton, Canada, and his colleagues tested DCA on human cells cultured outside the body and found that the lung, breast cancer and brains, but not kill healthy cells. The tumors in rats deliberately infected with human cancer also shrank drastically when they DCA-laced water for several weeks were fed.
DCA attacks a unique feature of cancer cells: the fact that their energy through the main body of the cell to make, rather than in mitochondria as in normal cells. This process, called glycolysis, is inefficint and put huge amounts of sugar. So far we assumed that cancer cells used glycolysis because their mitochondria were irreparably damaged. However, Michelakis's experiments prove this is not the case, because DCA mitochondria in cancer cells again aroused. And then destroyed the cancer cells died.
Michelakis suggests that the switch to glycolysis as an energy source occurs when cells in the middle of an abnormal but benign piece is not enough oxygen for their mitochondria to (see diagram) to bring to work properly. to survive, they eliminate their mitochondria, and begin to cause energy through glycolysis.
Crucially, though, mitochondria do another job in cells: they activate apoptosis, the process by which abnormal cells self-destruct. When the cells mitochondria off, they are immortal, living on other cells in the tumor and so becoming dominant. Once again awakened by DCA, mitochondria reactivate apoptosis and give instructions to the abnormal cells to die.
This also explains how secondary cancers form. The glycolysis produces lactic acid, that the collagen matrix holding cells together can break. This means abnormal cells can be released and float to other parts of the body, where they sow new tumors.
This ignites the old debate again or cancer or metabolic change is sparked. This research on metabolism tends to be designated as primary cause.
The University of Alberta and the Alberta Cancer Council are gengageerd to perform clinical trials in the immediate future in consultation with regulatory agencies such as Health Canada.
They believe that because DCA has been used in humans in Phase 1 and Phase 2 trials of metabolic diseases, cancer clinical trials timeline for our research will be much shorter than usual.
The drug, dichloroacetate (DCA), used for years to treat rare metabolic disorder and is known to be quite safe. It is also not protected by patents and hence could be very cheap, much cheaper than standard drugs against cancer.
The best part is that DCA (dichloroacetate) is actually the cancer cells by their mitochondria, their main power generator to reactivate sound makes that turn cells cancerous and the other is fatal. The drug benvloedt not the normal cells of the body.
Evangelos Michelakis of the University of Alberta in Edmonton, Canada, and his colleagues tested DCA on human cells cultured outside the body and found that the lung, breast cancer and brains, but not kill healthy cells. The tumors in rats deliberately infected with human cancer also shrank drastically when they DCA-laced water for several weeks were fed.
DCA attacks a unique feature of cancer cells: the fact that their energy through the main body of the cell to make, rather than in mitochondria as in normal cells. This process, called glycolysis, is inefficint and put huge amounts of sugar. So far we assumed that cancer cells used glycolysis because their mitochondria were irreparably damaged. However, Michelakis's experiments prove this is not the case, because DCA mitochondria in cancer cells again aroused. And then destroyed the cancer cells died.
Michelakis suggests that the switch to glycolysis as an energy source occurs when cells in the middle of an abnormal but benign piece is not enough oxygen for their mitochondria to (see diagram) to bring to work properly. to survive, they eliminate their mitochondria, and begin to cause energy through glycolysis.
Crucially, though, mitochondria do another job in cells: they activate apoptosis, the process by which abnormal cells self-destruct. When the cells mitochondria off, they are immortal, living on other cells in the tumor and so becoming dominant. Once again awakened by DCA, mitochondria reactivate apoptosis and give instructions to the abnormal cells to die.
This also explains how secondary cancers form. The glycolysis produces lactic acid, that the collagen matrix holding cells together can break. This means abnormal cells can be released and float to other parts of the body, where they sow new tumors.
This ignites the old debate again or cancer or metabolic change is sparked. This research on metabolism tends to be designated as primary cause.
The University of Alberta and the Alberta Cancer Council are gengageerd to perform clinical trials in the immediate future in consultation with regulatory agencies such as Health Canada.
They believe that because DCA has been used in humans in Phase 1 and Phase 2 trials of metabolic diseases, cancer clinical trials timeline for our research will be much shorter than usual.
Geen opmerkingen:
Een reactie posten